GE HealthCare Technologies Inc.GEHC
NasdaqGS•Healthcare•Medical Devices
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
GE HealthCare Technologies Inc. (GEHC) reported trailing twelve months revenue of $26.11B as of March 2026, a 6.2% increase year-over-year. Quarterly revenue reached $10.26B, reflecting continued top-line momentum.
GE HealthCare Technologies Inc. generated $7.75B in TTM net income, with quarterly EBITDA of $0. The operating margin contracted from 56.6% to 55.0%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (55.0%) and net margin (54.4%) indicates tight cost control with minimal non-operating drag. Net margin has narrowed from 55.0% a year ago, reflecting increased costs or interest expense.
GEHC trades at a P/S of N/A.
The company generated $0 in free cash flow over the trailing twelve months, indicating cash generation ability. The balance sheet shows $37.13B in total assets with $10.13B in long-term debt against $10.90B in stockholders equity for a debt-to-equity ratio of 0.9. Data based on the most recent quarterly reports.
Competitive analysis based on 18 quarters of fundamental data
Operating margins are positive at ~24.2% on average, but show some variability — pricing power may be sensitive to market conditions.
ROE averages 50.7% but has fluctuated — the competitive advantage may be cyclical or emerging.
5 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
TTM revenue has grown consistently (7 of 7 quarters up), with ~33.8% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 18 quarters
Margins are stable or improving at ~23.8% — no sign of cost or pricing stress.
FCF consistently trails net income (avg 9.5x) — earnings may be inflated by non-cash items or aggressive accounting.
Debt-to-equity has risen 29.5% recently — increasing financial risk even if the current ratio is manageable.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Shares decreased 100.0% — net buybacks are reducing shares outstanding and boosting per-share value.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation